KR20110058157A - The composition for the prevention and treatment of diabetic complications containing the extracts or fractions of herbal medicine as active ingredient - Google Patents
The composition for the prevention and treatment of diabetic complications containing the extracts or fractions of herbal medicine as active ingredient Download PDFInfo
- Publication number
- KR20110058157A KR20110058157A KR1020090114838A KR20090114838A KR20110058157A KR 20110058157 A KR20110058157 A KR 20110058157A KR 1020090114838 A KR1020090114838 A KR 1020090114838A KR 20090114838 A KR20090114838 A KR 20090114838A KR 20110058157 A KR20110058157 A KR 20110058157A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- fraction
- active ingredient
- composition
- diabetic complications
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 108
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 239000004480 active ingredient Substances 0.000 title claims abstract description 36
- 206010012655 Diabetic complications Diseases 0.000 title claims description 55
- 238000011282 treatment Methods 0.000 title claims description 17
- 230000002265 prevention Effects 0.000 title claims description 16
- 241000411851 herbal medicine Species 0.000 title 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000414274 Lithocarpus dealbatus Species 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 29
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000003674 animal food additive Substances 0.000 claims description 14
- 206010007749 Cataract diabetic Diseases 0.000 claims description 13
- 201000007025 diabetic cataract Diseases 0.000 claims description 13
- 230000003712 anti-aging effect Effects 0.000 claims description 11
- 239000012223 aqueous fraction Substances 0.000 claims description 10
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 10
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 239000002044 hexane fraction Substances 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 208000019622 heart disease Diseases 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 239000003918 blood extract Substances 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 239000012046 mixed solvent Substances 0.000 claims 1
- 102000016912 Aldehyde Reductase Human genes 0.000 abstract description 21
- 108010053754 Aldehyde reductase Proteins 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 19
- 239000002904 solvent Substances 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 38
- 238000004519 manufacturing process Methods 0.000 description 29
- 239000000469 ethanolic extract Substances 0.000 description 23
- 230000036252 glycation Effects 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 17
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000000605 extraction Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 239000007795 chemical reaction product Substances 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000005715 Fructose Substances 0.000 description 9
- 229930091371 Fructose Natural products 0.000 description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 230000013595 glycosylation Effects 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000401 methanolic extract Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- FWPVKDFOUXHOKQ-UHFFFAOYSA-N 2-[1-(carboxymethyl)cyclopentyl]acetic acid Chemical compound OC(=O)CC1(CC(O)=O)CCCC1 FWPVKDFOUXHOKQ-UHFFFAOYSA-N 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920005862 polyol Polymers 0.000 description 5
- 150000003077 polyols Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000001437 anti-cataract Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000003345 hyperglycaemic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 241000222350 Pleurotus Species 0.000 description 2
- 241000219492 Quercus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003288 aldose reductase inhibitor Substances 0.000 description 2
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 2
- 229950010170 epalrestat Drugs 0.000 description 2
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 2
- -1 ethyl oleate Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 108010004903 glycosylated serum albumin Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YVDMDAVAAHHPDH-UHFFFAOYSA-N 2-aminoguanidine Chemical compound NNC(N)=N.NNC(N)=N YVDMDAVAAHHPDH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 1
- 241001633106 Lithocarpus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of diabetic complications containing the extract as an active ingredient.
당뇨병(diabetes mellitus)은 전 세계적으로 중요한 성인병 중의 하나로서, 최근 우리나라에서도 급속한 경제 성장과 더불어 당뇨병 유병률이 10%에 달하며, 현재 전 세계적으로도 당뇨환자는 2억4천만 명이 넘었으며, 2025년에는 전 세계적으로 3억8천만 명으로 증가할 것이며, 이중 60%가 아시아 지역에서 발병할 것이라고 2009년 미국의사협회(JAMA)에서 발표하였다. 특히 당뇨발병시기가 중장년으로 당겨졌으며, 수명이 연장됨으로 인해서 합병증으로 진행되는 것은 피할 수 없는 상황이 되었다. 즉, 일반적으로 당뇨병에 걸린 후 10 ~ 20년이 지나면 체내 거의 모든 기관이 손상을 받아 당뇨성 망막병증(diabetic retinopathy), 당뇨성 백내 장(diabetic cataract), 당뇨성 신증(diabetic nephropathy), 당뇨성 신경병증(diabetic neuropathy), 심장병, 암 또는 골다공증 등이 나타난다. 만성 당뇨성 신증은 혈액 투석 치료 및 말기 신부전의 가장 중요한 원인이 되고 있으며, 당뇨성 백내장과 망막증은 실명을 초래하고 결국엔 죽음에 이르게 한다. 미국의 경우 25 ~ 74세 연령대의 실명의 원인이 당뇨병이며, 당뇨 발병 후 15 ~ 20년이 지나면 60%가 실명으로 이어진다. 그러므로 당뇨환자에게서 합병증이 발병하는 기간이 5 ~ 10년 정도 지연만 되더라도 환자와 그 가족의 삶의 질이 달라질 것이며, 국가재정에도 커다란 영향을 끼칠 것이다. Diabetes mellitus is one of the most important adult diseases in the world. In recent years, with the rapid economic growth in Korea, the prevalence of diabetes has reached 10%. Currently, there are more than 240 million diabetics worldwide. It will grow to 380 million worldwide, of which 60 percent will occur in Asia, according to the 2009 American Medical Association (JAMA). In particular, the onset of diabetes mellitus has been extended to middle age, and the prolonged lifespan has led to complications. That is, almost 10 to 20 years after diabetes, almost all organs in the body are damaged, diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic Diabetic neuropathy, heart disease, cancer or osteoporosis may appear. Chronic diabetic nephropathy is the most important cause of hemodialysis treatment and end stage renal failure. Diabetic cataracts and retinopathy lead to blindness and eventually death. In the United States, diabetes is the leading cause of blindness for ages 25-74, and 60% of blindness occurs 15 to 20 years after the onset of diabetes. Therefore, delaying the onset of complications in diabetic patients by 5 to 10 years will affect the quality of life of patients and their families and will have a major impact on national finances.
이러한 당뇨합병증을 유발하는 기전으로는 크게 단백질의 비효소적 당화반응(nonenzymatic glycation of protein), 폴리올 경로(polyol pathway) 및 산화적 스트레스(oxidative stress) 등으로 설명되고 있다. 단백질의 비효소적 당화반응(nonenzymatic glycation of protein)이란, 단백질의 리신 잔기 등의 아미노산 그룹과 환원당이 효소 작용 없는 축합반응, 즉 밀리아드 반응에 의한 것으로, 이 반응의 결과로 최종당화산물(advanced glycation endproducts, AGEs)이 생성된다. 단백질의 비효소적 당화반응은 (1) 단백질의 리신 잔기 등의 아미노산기와 환원당의 알데히드 또는 케톤이 효소 작용 없이 친핵성 첨가 반응을 하여 초기 단계 산물인 쉬프염기(schiff base)를 형성하고, 상기 쉬프염기와 인접한 케토아민 어닥트(ketoamine adduct)가 서로 축합하여 가역적인 아마도리(Amadori)형의 조기당화산물이 생성되는 단계 및 (2) 고혈당 상태가 지속되어 가역적인 아마도리형의 조기 당화산물이 분해되지 않고 재배열(rearrangement)되어 비가역산물인 최종당화산물이 생성되고, 이렇게 생성된 최종당화산물들이 단백질 또는 지질 등과 결합 또는 교차결합(cross-linking)하여 비가역적인 당화단백질 또는 당화지질 등의 산물이 생성되는 단계로 나눌 수 있다. 가역적인 아마도리형의 조기당화산물과 달리 최종당화산물은 비가역적인 반응 산물이므로, 일단 생성되면 혈당이 정상으로 회복되어도 분해되지 않고, 최종당화산물이 결합한 단백질 또는 지질의 생존기간 동안 조직에 축적되어 조직의 구조와 기능을 비정상적으로 변화시켜 조직 곳곳에서 합병증을 유발시킨다(Vinson, J. A. et al., 1996, J. Nutritinal Biochemistry 7: 559-663; Smith, P. R. et al., 1992, Eur . J. Biochem., 210: 729-739). 예를 들면, 포도당과 여러 종류의 단백질이 반응하여 생성된 최종당화산물 중 하나인 당화 알부민은 만성 당뇨성 신증을 일으키는 중요한 요인으로 작용한다. 당화 알부민은 당화가 진행되지 않은 정상 알부민에 비해 더 용이하게 신사구체 세포 내로 유입되고, 고농도의 포도당은 메산지움 세포를 자극하여 세포외 기질(extracellular matrix)합성을 증가시킨다. 과도하게 유입된 당화 알부민과 증가된 세포외 기질로 인하여 신사구체의 섬유화가 야기된다. 이와 같은 기전으로 신사구체가 계속 손상 받게 되어 혈액투석 또는 장기이식 등의 극단적인 치료방법을 쓸 수밖에 없는 단계에 이르게 되는 것이다. 또한, 만성 당뇨로 인하여 동맥벽에서는 콜라겐이, 신사구체에서는 기저막성 단백질이 최종당화산물과 결합되어 조직에 축적됨이 보고된바 있다(Brownlee, M., et al., 1986, Sciences, 232, 1629-1632). 이처럼 비효소적 단백질 당화반응에 의하여 기저막, 혈장 알부민, 수정체 단백질, 피브린, 콜라겐 등 의 단백질에서 당화가 일어나며, 생성된 최종당화산물이 조직의 구조와 기능을 비정상적으로 변화시켜 당뇨성 망막병증(diabetic retinopathy), 당뇨성 백내장(diabetic cataract), 당뇨성 신증(diabetic nephropathy), 당뇨성 신경병증(diabetic neuropathy) 등의 만성 당뇨합병증을 유발시킨다. 또한, 고혈당 상태에서 최종당화산물이 생성되는 과정에서 지질대사 이상이 일어나고 동시에 생성되는 유해한 산소 자유라디칼에 대한 방어시스템 기능이 저하되어 산화적 스트레스가 유발된다고 보고된바 있다(Yokozawa, T., et al, 2001, J. of Trad . Med., 18: 107-112). 이처럼 비효소적 당화반응과 산화적 스트레스(oxidative stress) 작용 기전이 서로 연관되어 있다. Mechanisms that induce diabetic complications are largely explained by nonenzymatic glycation of protein, polyol pathway, and oxidative stress. Nonenzymatic glycation of protein refers to the condensation reaction of amino acids such as lysine residues of proteins and reducing sugars due to enzymatic condensation reactions, that is, milliard reactions. glycation endproducts (AGEs). The non-enzymatic glycosylation of protein (1) an amino acid group such as a lysine residue of the protein and an aldehyde or ketone of a reducing sugar undergo a nucleophilic addition reaction without enzymatic action to form a Schiff base, which is an early product, The base and the adjacent ketoamine adduct condensate with each other to produce a reversible Amadori type of early glycosylated product, and (2) the hyperglycemic state is continued to degrade the reversible Amadori type of early glycated product. The final glycosylated product, which is an irreversible product, is produced by rearrangement, and the resulting glycosylated products are combined or cross-linked with proteins or lipids to produce an irreversible glycosylated protein or glycosylated lipid. Can be divided into the stages generated. Unlike the reversible amadori type of early glycosylated products, the final glycosylated product is an irreversible reaction product. Once produced, blood sugar does not decompose even when it is restored to normal. Abnormally alters the structure and function of the organs and causes complications throughout the tissue (Vinson, JA et al., 1996, J. Nutritinal Biochemistry 7: 559-663; Smith, PR et al., 1992, Eur . J. Biochem ., 210: 729-739). For example, glycated albumin, one of the final glycation products produced by the reaction of glucose and various proteins, is an important factor in causing chronic diabetic nephropathy. Glycosylated albumin is more easily introduced into renal glomeruli cells than normal albumin without glycosylation, and high concentrations of glucose stimulate mesangium cells to increase extracellular matrix synthesis. Excessively introduced glycated albumin and increased extracellular matrix result in fibrosis of the glomeruli. These mechanisms continue to damage the glomerulus, leading to the stage of extreme treatment methods such as hemodialysis or organ transplantation. In addition, chronic diabetes has been reported to accumulate collagen in the arterial wall and basal membrane protein in the renal glomeruli and to accumulate in tissues (Brownlee, M., et al., 1986, Sciences , 232, 1629-). 1632). As described above, glycosylation occurs in proteins such as the basement membrane, plasma albumin, lens protein, fibrin, and collagen by non-enzymatic protein glycosylation reactions. chronic diabetes complications such as retinopathy, diabetic cataract, diabetic nephropathy, and diabetic neuropathy. In addition, it has been reported that lipid metabolism abnormality occurs in the process of producing the final glycated product in hyperglycemic state and oxidative stress is induced by deterioration of defense system function against harmful oxygen free radicals (Yokozawa, T., et. al, 2001, J. of Trad . Med ., 18: 107-112. As such, the mechanism of action of non-enzymatic glycosylation and oxidative stress is related.
폴리올 경로란 (1) 알도스 또는 케토스로부터 알도스 환원효소(aldose reductase, AR)작용에 의해 환원되어 솔비톨을 형성하는 단계 및 (2) 솔비톨이 솔비톨 탈수소효소에 의해 산화되어 과당을 생성하는 단계로 이루어지는 과정이다. 정상상태에서는 알도스 환원효소가 포도당에 대하여 친화력이 매우 낮지만, 고혈당 상태에 의하여 폴리올 경로의 첫 번째 효소인 알도스 환원효소가 과도하게 활성화되어, 이로 인해 과도한 고혈당이 솔비톨과 과당으로 전환되어 조직에 축적되어 삼투압의 균형이 깨져 합병증이 유발된다. 즉, 증가한 삼투압으로 인하여 수분이 인입되어 당뇨성 망막병증(diabetic retinopathy), 당뇨성 백내장(diabetic cataract), 당뇨성 신경병증(diabetic neuropathy) 등으로 진행된다(김응진 외, 당뇨병학, 대한 당뇨병학회, 고려의학, 483쪽; Soulis-Liparota, T., et al., 1995, Diabetologia, 38: 357-394). 최종당화산물이 사람의 미세혈관 내피세포에서 폴리 올 경로의 주효소인 알도스 환원효소를 활성화시키는 것이 보고된바 있다(Nakamura, N., et al., 2000, Free Radic Biol . Med., 29: 17-25). 이때 과당은 포도당에 비하여 단백질의 비효소적 당화반응의 속도가 약 10배 정도 빠르다. 따라서 고농도의 과당이 단백질과 결합하여 결국은 최종당화산물의 형성을 가속화시킨다. 이와 같이, 비효소적 당화반응, 폴리올 경로 및 산화적 스트레스(oxidative stress) 작용 기전들이 서로 연관되어 당뇨합병증을 유발시킨다. 고혈당 상태에서 최종당화산물이 생성되는 과정에서 지질대사 이상이 일어나고 동시에 생성되는 유해한 산소 자유라디칼에 대한 방어시스템 기능이 저하되어 산화적 스트레스가 유발된다고 보고된바 있다(Yokozawa, T., et al, 2001, J. of Trad. Med., 18: 107-112). 따라서 비효소적 당화반응과 산화적 스트레스(oxidative stress) 작용 기전이 서로 연관되어 있다. 따라서, 당뇨합병증의 발병을 지연하거나 예방 또는 치료하기 위해서는 최종당화산물 형성의 억제가 매우 중요한 것으로 밝혀졌다(Brownlee, M., et al., 1988, N. Engl . Med ., 318, 1315-1321).The polyol pathway is (1) reduced by aldose reductase (AR) action from aldose or ketose to form sorbitol, and (2) sorbitol is oxidized by sorbitol dehydrogenase to produce fructose. The process consists of. At steady state, aldose reductase has a very low affinity for glucose, but the hyperglycemic state causes excessive activation of aldose reductase, the first enzyme in the polyol pathway, resulting in the conversion of excess hyperglycemia into sorbitol and fructose. Accumulation in the osmotic balance is broken, causing complications. In other words, due to the increased osmotic pressure, water is introduced and progresses to diabetic retinopathy, diabetic cataract, diabetic neuropathy (Kim Eung-jin et al., Diabetes, Korean Diabetes Association, Korea Medicine, p. 483; Soulis-Liparota, T., et al., 1995, Diabetologia , 38: 357-394). Final glycation end products have been reported to activate aldose reductase, a major enzyme of the polyol pathway, in human microvascular endothelial cells (Nakamura, N., et al., 2000, Free Radic Biol . Med ., 29: 17-25). At this time, fructose is about 10 times faster than non-enzymatic glycosylation of protein. Thus, high concentrations of fructose bind to the protein and eventually accelerate the formation of the final glycated product. As such, non-enzymatic glycosylation, polyol pathways, and oxidative stress mechanisms of action are linked to each other to cause diabetic complications. It has been reported that lipid metabolism abnormalities occur in the process of producing the final glycated product in hyperglycemic state and oxidative stress is caused by deterioration of defense system function against harmful oxygen free radicals (Yokozawa, T., et al, 2001, J. of Trad. Med., 18: 107-112. Therefore, non-enzymatic glycosylation and oxidative stress mechanisms of action are interrelated. Therefore, in order to delay, prevent or treat the development of diabetic complications, the final glycated product Inhibition of formation has been found to be very important (Brownlee, M., et al., 1988, N. Engl . Med . , 318, 1315-1321).
현재, 단백질 당화 억제제로 합성제제인 아미노구아니딘(aminoguanidine)은 친핵성 히드라진(hydrazine)으로, 아마도리 산물과 결합하여 단백질과의 교차결합을 방지함으로써 최종당화산물의 생성을 억제하여 합병증으로 진전되는 것을 지연 또는 방지한다(Brownlee, M., et al., 1986, Sciences, 232, 1629-1632; Edelstein, D. et al., 1992, Diabetes, 41, 26-29). 아미노구아니딘은 당뇨합병증의 예방 및 치료에 가장 유망한 합성 의약품으로 제 3상 임상실험까지 진행되었 으나, 장기간 투여 시 독성이 유발되는 문제점이 나타나 중단되었다. 그러므로 안전하고 효능이 우수한 천연약제의 개발이 요망되고 있는 실정이다.Currently, aminoguanidine, a synthetic agent as a protein glycosylation inhibitor, is a nucleophilic hydrazine, which binds with the amadori product and prevents cross-linking with the protein, thereby inhibiting the production of the final glycation product and progressing to complications. Delay or prevent (Brownlee, M., et al., 1986, Sciences , 232, 1629-1632; Edelstein, D. et al., 1992, Diabetes , 41, 26-29). Aminoguanidine is the most promising synthetic drug for the prevention and treatment of diabetic complications and has been conducted until phase III clinical trials. Therefore, the development of safe and effective natural medicine is desired.
백피가(白皮柯)(Lithocarpus dealbatus Hook. f. et Thomas. 또는 Quercus dealbatus Hook. f. et Thomas.)는 꿀풀과(Rubiaceae)에 속하는 상록관목으로, 높이는 5 ~ 10 미터이며, 꽃과 과일은 8 ~ 10월에 피고 열린다. 중국의 사천, 귀주 및 운님 등에 분포한다. 백피가는 한의학적으로 맛은 고(苦: bitter taste)하고 온(溫:warm)하며, 기생충으로 인한 복통(충적복통: 蟲積腹痛: abdominal pain due to intestinal parasitosis)에 사용되었다(중화본초, 상해과학기술출판사, Vol. 2, 0949; ISBN 7-5323-5106-8/R.1287). 그러나 현대의학적인 약리작용 및 성분학적 연구가 전혀 보고되지 않았고, 당뇨병 또는 당뇨합병증에 관한 백피가의 효능은 밝혀진 바가 없다. Lithocarpus dealbatus Hook. f. et Thomas. Or Quercus dealbatus Hook. f. et Thomas.) is an evergreen shrub belonging to the Rubiaceae family, 5-10 m high, with flowers and fruits blooming and opening in August-October. It is distributed in Sichuan, Guizhou and Yunim of China. Baekpiga is a oriental medicine with a bitter taste and warmness, and has been used for abdominal pain due to intestinal parasitosis. Technical Publications, Vol. 2, 0949; ISBN 7-5323-5106-8 / R.1287). However, no modern pharmacological and component studies have been reported, and the efficacy of Baekpiga on diabetes or diabetic complications has not been revealed.
이에 본 발명자들은 당뇨합병증을 위한, 독성 및 부작용이 거의 없어 안전하고 효과적인 천연 약재를 개발하던 중, 백피가 추출물 또는 이의 분획물이 최종당화산물 및 알도즈 환원효소 생성을 억제함으로써 강력한 당뇨합병증 억제 활성을 나타내고, 노화방지 또는 항암 작용 효능이 있음을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors are developing a safe and effective natural medicine for the diabetic complications with little toxicity and side effects, and the extract or fraction thereof from Baekpiga inhibits the production of the final glycation product and aldose reductase, thereby enhancing potent diabetic complications. The present invention was completed by confirming the anti-aging or anti-cancer effect.
본 발명의 목적은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for preventing and treating diabetic complications, which contains the extract or its fraction as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 백피가(Lithocarpus dealbatus Hook.) 추출물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention is Baekpiga ( Lithocarpus dealbatus Hook.) Provides a composition for preventing and treating diabetic complications containing the extract as an active ingredient.
또한, 본 발명은 백피가 추출물을 추가적으로 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물을 제공한다.The present invention also provides a composition for the prevention and treatment of diabetic complications containing the fraction prepared by dividing the extract with an additional organic solvent as an active ingredient.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 개선용 건강기능식품을 제공한다.In addition, the present invention provides a dietary supplement for preventing and improving diabetic complications containing white extract as an active ingredient extract or fractions thereof.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 개선용 기능성 사료첨가제를 제공한다.In another aspect, the present invention provides a functional feed additive for preventing and improving diabetic complications containing the extract or its fraction as an active ingredient.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 최종당화산물 억제용 조성물을 제공한다.In another aspect, the present invention provides a composition for inhibiting the final glycation product containing the extract as an active ingredient in the extract.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화방지 및 지연용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for anti-aging and delaying, containing the extract or fractions thereof as an active ingredient.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화방지 및 지연용 건강기능식품을 제공한다.In addition, the present invention provides anti-aging and delayed health functional food containing a white skin extract or fractions thereof as an active ingredient.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing and treating cancer, which contains the extract or fraction thereof as an active ingredient.
아울러, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 암 예방 및 개선용 건강기능식품을 제공한다.In addition, the present invention provides a dietary supplement for cancer prevention and improvement, containing Baekpi as an active ingredient extract or fractions thereof.
본 발명의 백피가 추출물 또는 이의 분획물은 당뇨합병증 발병의 지표인 최종당화산물의 생성을 억제하고, 알도즈 환원효소의 활성을 억제하며, 항백내장 효과를 통해 뛰어난 당뇨합병증 억제 활성을 나타내므로, 당뇨합병증 예방 및 치료용 조성물의 유효성분으로서 유용하게 사용될 수 있다.Baekpiga extract or fractions thereof of the present invention inhibits the production of the final glycation product, which is an indicator of the development of diabetic complications, inhibits the activity of the aldose reductase, and exhibits excellent antidiabetic complications through the anti-cataract effect, It can be usefully used as an active ingredient of a composition for preventing and treating complications.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 백피가(Lithocarpus dealbatus Hook.) 추출물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물을 제공한다.The present invention is Baekpiga ( Lithocarpus dealbatus Hook.) Provides a composition for preventing and treating diabetic complications containing the extract as an active ingredient.
또한, 본 발명은 백피가 추출물을 추가적으로 유기용매로 분획하여 제조한 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 조성물을 제공한다.The present invention also provides a composition for the prevention and treatment of diabetic complications containing the fraction prepared by dividing the extract with an additional organic solvent as an active ingredient.
상기 당뇨합병증은 당뇨성 망막병증, 당뇨성 백내장, 당뇨성 신증, 당뇨성 신경병증, 심장병, 암, 골다공증, 및 아테롬성 동맥경화로 구성된 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다. 당뇨합병증은 당뇨병이 장기간 지속될 경우 유발되는 증상이지만, 당뇨병의 발병 기준 및 판단 기준과 상이하며, 당뇨합병증 치료제는 당뇨병 치료제와는 별개로서 사용될 수 있다.The diabetic complication is preferably any one selected from the group consisting of diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, heart disease, cancer, osteoporosis, and atherosclerosis. Diabetes complications are symptoms caused by long-term diabetes mellitus, but differ from the onset criteria and judgment criteria of diabetes mellitus, and the treatment for diabetic complications can be used separately from the diabetes treatment.
상기 백피가 추출물은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다:The white skin extract is preferably prepared by a manufacturing method comprising the following steps, but not always limited thereto:
1) 백피가(Lithocarpus dealbatus Hook.)에 추출용매를 가하여 추출하는 단계;1) extracting by adding an extraction solvent to Lithocarpus dealbatus Hook.
2) 단계 1)의 추출물을 식힌 후 여과하는 단계; 및2) cooling the extract of step 1) and then filtering; And
3) 단계 2)의 여과한 추출물을 감압 농축한 후 건조하는 단계.3) drying the filtered extract of step 2) under reduced pressure.
상기 방법에 있어서, 단계 1)의 백피가는 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 상기 백피가는 식물 전체를 이용할 수 있고, 줄기를 이용하는 것이 바람직하나 이에 한정하지 않는다.In the above method, the Baekpiga of step 1) can be used without limitation, such as cultivated or commercially available. The baekpiga can use the entire plant, it is preferable to use a stem, but is not limited thereto.
상기 추출용매는 물, 알코올 또는 이들의 혼합물을 사용하는 것이 바람직하다. 상기 알코올로는 C1 내지 C4 저급 알코올을 이용하는 것이 바람직하고, 상기 저급 알코올로는 에탄올 또는 메탄올을 이용하는 것이 바람직하며, 80% 에탄올을 이용하는 것이 더욱 바람직하나 이에 한정하지 않는다. 추출 방법으로는 여과법, 열수추출, 침지추출, 환류냉각추출 및 초음파추출 등 당업계의 통상적인 방법을 이용할 수 있으며, 열수추출 방법으로 1회 내지 5회 추출하는 것이 바람직하며, 3회 반복 추출하는 것이 더욱 바람직하나 이에 한정하지 않는다. 상기 추출용매는 건조된 백피가 줄기 중량에 1 내지 10배 첨가할 수 있으며, 1 내지 5배 첨가하는 것이 바람직하다. 추출온도는 20 내지 30℃인 것이 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 24 내지 48시간인 것이 바람직하나 이에 한정하지 않는다.The extraction solvent is preferably water, alcohol or a mixture thereof. It is preferable to use C 1 to C 4 lower alcohol as the alcohol, it is preferable to use ethanol or methanol as the lower alcohol, more preferably 80% ethanol, but is not limited thereto. As extraction methods, conventional methods in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction, can be used, and the extraction is preferably performed once to five times by hot water extraction, and three times to extract repeatedly. More preferably, but is not limited thereto. The extraction solvent may be added 1 to 10 times the weight of the dried white skin stem, preferably 1 to 5 times. The extraction temperature is preferably 20 to 30 ° C., but is not limited thereto. In addition, the extraction time is preferably 24 to 48 hours, but is not limited thereto.
상기 방법에 있어서, 단계 3)의 감압농축은 진공감압농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하나 이에 한정하지 않는다. In the above method, the decompression concentration in step 3) preferably uses a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
본 발명의 구체적인 실시태양에 있어서, 백피가 줄기를 물로 세척한 후, 그늘에서 건조시켰다. 건조된 백피가 줄기를 분쇄하여 추출용기에 넣고, 추출용매로 상온에서 반복 추출하였다. 백피가 추출물을 수득한 후, 거름종이 등을 이용하여 고형분을 제거하고 여과하였다. 상기 추출액을 감압 농축하여 백피가 추출물을 제조하였다.In a specific embodiment of the present invention, the white skin was washed with water and then dried in the shade. Dried white skin was pulverized, put the stem into an extraction container, and extracted repeatedly at room temperature with an extraction solvent. After the white skin obtained the extract, the solids were removed using a filter paper or the like and filtered. The extract was concentrated under reduced pressure to prepare an extract of Baekpiga.
상기 백피가 추출물의 분획물은 백피가 추출물에 추가적으로 유기용매를 가하여 유기용매 분획물을 제조하는 단계를 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다.The fraction of the Baekpiga extract is preferably prepared by a manufacturing method comprising the step of preparing an organic solvent fraction by adding an organic solvent to the Baekpiga extract is not limited thereto.
상기 방법에 있어서, 상기 유기용매는 노르말-헥산, 에틸아세테이트 또는 노르말-부탄올인 것이 바람직하나 이에 한정하지 않는다. 상기 분획물은 상기 백피가 추출물로부터 분획 과정을 1 내지 5회, 바람직하게는 3회 반복하여 수득할 수 있고, 분획 후 감압 농축하는 것이 바람직하나 이에 한정하지 않는다.In the above method, the organic solvent is preferably, but not limited to, normal-hexane, ethyl acetate or normal-butanol. The fraction may be obtained by repeating the fractionation process 1 to 5 times, preferably three times, from the extract of the baekpi, preferably concentrated under reduced pressure after the fraction, but is not limited thereto.
상기 분획물은 백피가 추출물을 물에 현탁시킨 후 노르말-헥산, 에틸아세테이트, 노르말-부탄올 및 물로 순차적으로 계통 분획하여 수득한 노르말-헥산 분획물, 에틸아세테이트 분획물, 노르말-부탄올 분획물 또는 물 분획물 중 어느 하나인 것이 바람직하나 이에 한정하지 않는다. The fraction is any one of normal-hexane fractions, ethyl acetate fractions, normal-butanol fractions or water fractions obtained by suspending the extract in water and then systematically fractionating the mixture into normal-hexane, ethyl acetate, normal-butanol and water. Is preferably, but is not limited thereto.
본 발명의 구체적인 실시태양에 있어서, 상기 백피가 추출물에서 용매를 증발시키고 수득한 잔사에 물과 노르말-헥산을 넣어 노르말-헥산층을 분리하여 노르말-헥산 분획물을 수득하였다. 헥산층을 제외한 물층에 에틸아세테이트를 혼합한 후 에틸아세테이트층을 분리하여 에틸아세테이트 분획물을 얻었다. 또한, 에틸아세테이트층을 제거한 후 노르말-부탄올을 혼합한 후 노르말-부탄올층을 분리하여 노르말-부탄올 분획물을 수득하였다. 마지막으로 노르말-부탄올층을 제거한 후 물층의 물 분획물을 수득하였다In a specific embodiment of the present invention, the solvent was evaporated from the extract of the white skin and water and normal-hexane were added to the obtained residue to separate the normal-hexane layer to obtain a normal-hexane fraction. Ethyl acetate was mixed with the water layer except for the hexane layer, and the ethyl acetate layer was separated to obtain an ethyl acetate fraction. Also, after removing the ethyl acetate layer, normal-butanol was mixed and the normal-butanol layer was separated to obtain a normal-butanol fraction. Finally, after removing the normal-butanol layer, a water fraction of the water layer was obtained.
본 발명자들은 당뇨합병증의 지표 및 치료 효능 평가의 지표가 되는 최종당화산물의 생성억제 효능을 분석하기 위하여, 단백질로 소혈청알부민(bovine serum albumin; BSA)을 이용하여 과당 및 글루코스와의 결합 정도를 지표로 이용하였다. 또한, 양성대조군으로는 최종당화산물에 대한 억제 효능이 매우 우수하다고 알려진 아미노구아니딘(aminoguanidine)을 이용하였다. 그 결과, 백피가 추출물 또는 이의 분획물을 처리한 시험군이 기존에 알려진 아미노구아니딘에 비해 훨씬 효과적으로 최종당화산물 억제 효능을 나타냄을 확인하였다(표 1 참조).The present inventors used bovine serum albumin (BSA) as a protein to analyze the degree of binding of fructose and glucose in order to analyze the inhibitory effect of the production of the final glycation glycoside which is an indicator of diabetic complications and evaluation of therapeutic efficacy. It was used as an indicator. In addition, as a positive control group was used aminoguanidine (aminoguanidine) is known to have a very good inhibitory effect on the final glycated product. As a result, it was confirmed that the test group treated with the extract or fractions thereof showed more effective inhibition of the end glycated product than the previously known aminoguanidine (see Table 1).
본 발명자들은 백피가 추출물 또는 이의 분획물의 당뇨합병증의 또 다른 지표가 되는 알도즈 환원효소의 활성 억제를 측정하였다. 비교 대조군으로는 3,3-테 트라메칠렌글루타르산을 이용하여 측정하였다. 그 결과, 본 발명의 백피가 추출물 또는 이의 분획물은 기존에 알려진 알도즈 환원효소 억제제에 비하여 더 효과적으로 알도즈 환원효소 활성을 억제하는 것으로 나타났다(표 2 참조).The present inventors measured the inhibition of the activity of aldose reductase, in which leukpi was another indicator of diabetic complications of the extract or fractions thereof. As a comparative control, it was measured using 3,3-tetramethyleneglutaric acid. As a result, it was shown that the Baekgai extract or fractions thereof of the present invention inhibit aldose reductase activity more effectively than the known aldose reductase inhibitors (see Table 2).
본 발명자들은 생체 외(ex vivo) 실험을 통하여 수정체 혼탁에 대한 백피가 추출물의 효능을 확인하였다. 그 결과, 수정체가 혼탁되는 백내장 유발을 유의성 있게 억제하는 것으로 나타났다(도 1 참조).The inventors of the invention in vitro ( ex In vivo ) experiments confirmed the efficacy of the extracts of the baekpiga on lens turbidity. As a result, it was shown to significantly inhibit the induction of cataracts in which the lens becomes cloudy (see FIG. 1).
이에, 본 발명의 백피가 추출물 또는 이의 분획물은 당뇨합병증의 원인이며, 당뇨합병증 치료제의 효능 평가의 척도가 되는 최종당화산물에 대한 생성 저해 효과, 알도즈 환원효소 활성 억제효과 및 항백내장 효능이 우수한 것으로 나타났으므로, 당뇨합병증 예방 및 치료용 조성물의 유효성분으로서 유용하게 사용될 수 있다.Thus, Baekpiga extract or fractions thereof of the present invention is a cause of diabetic complications, excellent production inhibitory effect on the final glycated product, which is a measure of the efficacy of the treatment of diabetic complications, aldose reductase activity inhibitory effect and excellent anti-cataract efficacy Since it has been shown, it can be usefully used as an active ingredient of the composition for preventing and treating diabetic complications.
본 발명의 조성물 총 중량에 대하여 본 발명의 백피가 추출물 또는 이의 분획물을 0.1 내지 99.9 중량%를 유효성분으로 함유하고, 약제학적으로 허용가능한 담체, 부형제 또는 희석제를 포함할 수 있다. Based on the total weight of the composition of the present invention, the white blood of the present invention contains 0.1 to 99.9% by weight of the extract or fractions thereof as an active ingredient, and may include a pharmaceutically acceptable carrier, excipient or diluent.
본 발명의 조성물은 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제 및 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The compositions of the present invention may be in various oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 조성물은 경구 또는 비경구로 투여될 수 있으며, 비경구 투여시 피부외용 또는 복강내, 직장, 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사 방식을 선택하는 것이 바람직하며, 가장 바람직하게는 피부외용으로 사용한다.The composition of the present invention may be administered orally or parenterally, and it is preferable to select externally or intraperitoneally, rectally, intravenously, intramuscularly, subcutaneously, intrauterine epidural or cerebrovascular injection methods for parenteral administration. For skin use externally.
본 발명의 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 그 범위가 다양하며, 일일 투여량은 백피가 추출물 또는 이의 분획물의 양을 기준으로 0.01 내지 1000 ㎎/㎏이고, 바람직하게는 30 내지 500 ㎎/㎏이고, 더욱 바람직하게는 50 내지 300 ㎎/㎏이며, 하루 1 ~ 6 회 투여될 수 있다. The dosage of the composition of the present invention varies depending on the weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate and severity of the disease of the patient, the daily dosage is the extract of Baekpiga or its It is 0.01 to 1000 mg / kg, preferably 30 to 500 mg / kg, more preferably 50 to 300 mg / kg, based on the amount of fraction, and can be administered 1 to 6 times a day.
본 발명의 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.
또한, 본 발명은 약학적으로 유효한 양의 상기 백피가 추출물 또는 이의 분획물을 개체에 투여하는 단계를 포함하는 당뇨합병증 예방 및 치료 방법을 제공한다.The present invention also provides a method for preventing and treating diabetic complications, comprising administering to a subject a pharmaceutically effective amount of the extract or fraction thereof.
상기 개체는 척추동물이고 바람직하게는 포유동물이며, 그보다 바람직하게는 쥐, 토끼, 기니아피크, 햄스터, 개, 고양이와 같은 실험동물이고, 가장 바람직하게는 침팬지, 고릴라와 같은 유인원류 동물이다.The subject is a vertebrate and preferably a mammal, more preferably an experimental animal such as a rat, rabbit, guinea pig, hamster, dog, cat, and most preferably an ape-like animal such as a chimpanzee or gorilla.
상기 투여방법은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 복강내주사, 직장내주사, 피하주사, 정맥주사, 근육내 주사, 자궁내 경막 주사, 뇌혈관내(intracerebroventricular) 주사 또는 흉부내 주사에 의해 투여될 수 있다.The method of administration may be administered orally or parenterally, intraperitoneal, rectal, subcutaneous, intravenous, intramuscular, intrauterine dural, intracerebroventricular or intrathoracic It can be administered by injection.
상기 약학적으로 유효한 양이란 0.0001 내지 100 ㎎/㎏이고, 바람직하게는 0.001 내지 10 ㎎/㎏이며, 이에 한정하지 않는다. 투여량은 특정 환자의 체중, 연령, 성별, 건강상태, 식이, 투여기간, 투여방법, 제거율, 질환의 중증도 등에 따라 변화될 수 있다.The pharmaceutically effective amount is 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, but is not limited thereto. Dosage may vary depending on the weight, age, sex, health status, diet, duration of administration, method of administration, elimination rate, severity of disease, and the like of a particular patient.
상기 당뇨합병증은 당뇨성 망막병증, 당뇨성 백내장, 당뇨성 신증, 당뇨성 신경병증, 심장병, 암, 골다공증, 및 아테롬성 동맥경화로 구성된 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다. The diabetic complication is preferably any one selected from the group consisting of diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, heart disease, cancer, osteoporosis, and atherosclerosis.
본 발명의 백피가 추출물 또는 이의 분획물은 최종당화산물의 생성 및 알도즈 환원효소의 활성을 억제하고, 수정체 혼탁도를 감소시켜 당뇨성 백내장에 대한 억제 효과를 나타냄으로써 당뇨합병증을 효과적으로 억제함을 확인하였으므로, 당뇨합병증의 예방 및 치료에 유용하게 사용될 수 있다.Baekpiga extract or fractions thereof of the present invention effectively inhibits diabetic complications by inhibiting the production of the final glycation end products and the activity of aldose reductase, reducing the turbidity of the lens to exhibit an inhibitory effect on diabetic cataracts. Therefore, it can be usefully used for the prevention and treatment of diabetic complications.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 개선용 건강기능식품을 제공한다.In addition, the present invention provides a dietary supplement for preventing and improving diabetic complications containing white extract as an active ingredient extract or fractions thereof.
상기 당뇨합병증은 당뇨성 망막병증, 당뇨성 백내장, 당뇨성 신증, 당뇨성 신경병증, 심장병, 암, 골다공증, 및 아테롬성 동맥경화로 구성된 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다. The diabetic complication is preferably any one selected from the group consisting of diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, heart disease, cancer, osteoporosis, and atherosclerosis.
본 발명의 백피가 추출물 또는 이의 분획물은 최종당화산물의 생성 및 알도즈 환원효소의 활성을 억제하고, 수정체 혼탁도를 감소시켜 당뇨성 백내장에 대한 억제 효과를 나타냄으로써 당뇨합병증을 효과적으로 억제함을 확인하였으므로, 당뇨합병증의 예방 및 개선용 건강기능식품에 유용하게 사용될 수 있다.Baekpiga extract or fractions thereof of the present invention effectively inhibits diabetic complications by inhibiting the production of the final glycation end products and the activity of aldose reductase, reducing the turbidity of the lens to exhibit an inhibitory effect on diabetic cataracts. Therefore, it can be usefully used in the health functional food for the prevention and improvement of diabetic complications.
본 발명의 기능성 식품은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강식품 100 중량부당 0.01~0.04 중량부, 바람직하게는 약 0.02 ~ 0.03 중량부 범위에서 선택하는 것이 바람직하다.The functional food of the present invention may contain various flavors, natural carbohydrates, and the like as additional ingredients. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is preferably selected in the range of 0.01 to 0.04 parts by weight, preferably about 0.02 to 0.03 parts by weight, per 100 parts by weight of the health food of the present invention.
상기 외에 본 발명의 기능성 식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 기능성 식품은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 건강식품 100 중량부당 0.01~0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonation agents used in carbonated beverages. In addition, the functional food of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. Although the ratio of such an additive is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 개선용 기능성 사료첨가제를 제공한다.In another aspect, the present invention provides a functional feed additive for preventing and improving diabetic complications containing the extract or its fraction as an active ingredient.
상기 당뇨합병증은 당뇨성 망막병증, 당뇨성 백내장, 당뇨성 신증, 당뇨성 신경병증, 심장병, 암, 골다공증, 및 아테롬성 동맥경화로 구성된 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정하지 않는다. The diabetic complication is preferably any one selected from the group consisting of diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, heart disease, cancer, osteoporosis, and atherosclerosis.
본 발명의 백피가 추출물 또는 이의 분획물은 최종당화산물의 생성 및 알도즈 환원효소의 활성을 억제하고, 수정체 혼탁도를 감소시켜 당뇨성 백내장에 대한 억제 효과를 나타냄으로써 당뇨합병증을 효과적으로 억제함을 확인하였으므로, 당뇨합병증의 예방 및 개선용 기능성 사료첨가제에 유용하게 사용될 수 있다.Baekpiga extract or fractions thereof of the present invention effectively inhibits diabetic complications by inhibiting the production of the final glycation end products and the activity of aldose reductase, reducing the turbidity of the lens to exhibit an inhibitory effect on diabetic cataracts. Therefore, it can be usefully used in the functional feed additive for the prevention and improvement of diabetic complications.
상기 사료첨가제는 가금류, 가축 등에게 꾸준히 섭취하게 함으로써 당뇨합병증을 예방할 수 있고, 이미 발생한 당뇨합병증을 치료할 수 있다. The feed additives can be prevented from diabetic complications by steadily ingesting poultry, livestock, and the like, and can treat already occurring diabetic complications.
본 발명의 사료첨가제에는 상기 백피가 추출물 또는 이의 분획물이 0.1 ~ 20% 중량부, 지방분해효소(lipase)가 0.001 ~ 0.01% 중량부, 제 3 인산칼슘이 1 ~ 20% 중량부, 비타민E가 0.01 ~ 0.1% 중량부, 효소분말이 1 ~ 10% 중량부, 유산균이 0.1 ~ 10% 중량부, 바실러스(bacillus) 배양액이 0.01 ~ 10% 중량부 및 포도당은 20 ~ 90% 중량부로 구성되어 있는 것이 바람직하나, 특별히 이에 한정하지 않으며, 백피가 추출물 또는 이의 분획물이 유효량으로 첨가되어 있다면, 본 발명의 사료첨가제로서 이용 가능하다. The feed additive of the present invention contains 0.1 to 20% by weight of the extract or fraction thereof, lipase 0.001 to 0.01% by weight, 1 to 20% by weight of the third calcium phosphate, vitamin E 0.01 to 0.1% by weight of enzyme powder, 1 to 10% by weight of enzyme powder, 0.1 to 10% by weight of lactic acid bacteria, 0.01 to 10% by weight of Bacillus culture medium and 20 to 90% by weight of glucose. It is preferred, but not particularly limited thereto, and if it is added in an effective amount of the extract or fractions thereof, it can be used as a feed additive of the present invention.
상기 유효량이란, 가금류, 가축 등이 꾸준히 섭취하게 함으로써 당뇨합병증을 예방하거나, 이미 발생한 당뇨합병증을 치료할 수 있는 양을 의미한다. 또한, 첨가에 의한 이익을 넘는 악영향이 생기지 않는 양이 바람직하다.The effective amount refers to an amount capable of preventing diabetic complications or treating already occurring diabetic complications by continuously ingesting poultry and livestock. Moreover, it is preferable that the quantity which does not produce the bad influence beyond the benefit by addition is preferable.
또한 상기 사료첨가제는 추가적으로 가금류 및 가축 등에 허용되는 담체를 함유할 수 있다. 본 발명에 있어서는 상기 사료첨가제를 그대로 또는 공지의 담체, 안정제 등을 가할 수 있으며, 필요에 따라 비타민, 아미노산류, 미네랄 등의 각종 양분, 항산화제, 항생물질, 항균제 및 기타의 첨가제 등을 가할 수도 있으며, 그 형상으로서는 분체, 과립, 펠릿, 현탁액 등의 적당한 상태일 수 있다. 본 발명의 사료첨가제를 공급하는 경우는 가금류 및 가축 등에 대하여 단독으로 또는 사료에 혼합하여 공급할 수 있다. In addition, the feed additive may additionally contain a carrier that is acceptable to poultry and livestock. In the present invention, the feed additive may be added as it is or a known carrier, stabilizer and the like, and various nutrients such as vitamins, amino acids and minerals, antioxidants, antibiotics, antibacterial agents and other additives may be added as necessary. The shape may be in a suitable state such as powder, granules, pellets, suspension, or the like. When supplying the feed additive of the present invention can be supplied alone or mixed in the feed for poultry and livestock.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 최종당화산물 억제용 조성물을 제공한다.In another aspect, the present invention provides a composition for inhibiting the final glycation product containing the extract as an active ingredient in the extract.
본 발명의 백피가 추출물 또는 이의 분획물은 최종당화산물의 생성 및 알도즈 환원효소의 활성을 억제하고, 수정체 혼탁도를 감소시켜 당뇨성 백내장에 대한 억제 효과를 나타냄으로써 당뇨합병증을 효과적으로 억제함을 확인하였으므로, 당뇨합병증의 지표인 최종당화산물 억제용 조성물의 유효성분으로 유용하게 사용될 수 있다.Baekpiga extract or fractions thereof of the present invention effectively inhibits diabetic complications by inhibiting the production of the final glycation end products and the activity of aldose reductase, reducing the turbidity of the lens to exhibit an inhibitory effect on diabetic cataracts. Therefore, it can be usefully used as an active ingredient of the composition for inhibiting the final glycation product that is an indicator of diabetic complications.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화방지 및 지연용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for anti-aging and delaying, containing the extract or fractions thereof as an active ingredient.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화방지 및 지연용 건강기능식품을 제공한다.In addition, the present invention provides anti-aging and delayed health functional food containing a white skin extract or fractions thereof as an active ingredient.
최종당화산물이 생성되는 과정에서 지질대사 이상이 일어나고 동시에 생성되는 유해한 산소 자유라디칼에 대한 방어시스템 기능이 저하되어 산화적 스트레스가 유발된다고 보고된 바(Yokozawa, T., et al, 2001, J. of Trad . Med., 18: 107-112), 본 발명의 백피가 추출물 또는 이의 분획물은 최종당화산물의 생성을 효과적으로 억제하므로, 노화방지 및 지연용 약학적 조성물 또는 건강기능식품에 유용하게 사용될 수 있다.It has been reported that lipid metabolism abnormalities occur during the production of final glycation end products, and that oxidative stress is induced by deterioration of defense system function against harmful oxygen free radicals (Yokozawa, T., et al, 2001, J.). of Trad . Med ., 18: 107-112), Baekpiga extract or fractions thereof of the present invention effectively inhibits the production of the end glycated product, it can be useful in anti-aging and delayed pharmaceutical composition or dietary supplement.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 당뇨병에 걸린 개체에 투여하는 단계를 포함하는 노화방지 및 지연 방법을 제공한다.The present invention also provides an anti-aging and delaying method comprising administering an extract or a fraction thereof to a subject with diabetes.
본 발명의 백피가 추출물 또는 이의 분획물은 최종당화산물의 생성을 효과적으로 억제하므로, 노화방지 및 지연을 위해 유용하게 사용될 수 있다.Baekpiga extract or fractions thereof of the present invention effectively inhibits the production of the end glycated product, it can be usefully used for anti-aging and delay.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 항암 예방 및 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for the prevention and treatment of cancer, which contains the extract or fraction thereof as an active ingredient.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 유효성분으로 함유하는 항암 예방 및 개선용 건강기능식품을 제공한다.In addition, the present invention provides anti-cancer anti-cancer functional foods containing white extract as an active ingredient extract or fractions thereof.
최종당화산물이 암을 유발한다는 것이 이미 보고되었는바(Tokuda H. et al., 2005, Book of Abstract of 53rd GA Congress joint with SIF, P076), 본 발명의 백피가 추출물 또는 이의 분획물은 최종당화산물의 생성을 효과적으로 억제하므로, 암 치료 및 예방용 약학적 조성물 또는 암 치료 및 개선용 건강기능식품에 유용하게 사용될 수 있다.It has already been reported that final glycation end products are cancer-causing (Tokuda H. et al., 2005, Book of Abstract of 53rd GA Congress joint with SIF, P076). Since it effectively inhibits the production of cancer, it can be usefully used in the pharmaceutical composition for the treatment and prevention of cancer or the dietary supplement for cancer treatment and improvement.
또한, 본 발명은 백피가 추출물 또는 이의 분획물을 암에 걸린 개체에 투여하는 단계를 포함하는 암 예방 및 치료방법을 제공한다.In addition, the present invention provides a method for preventing and treating cancer comprising the step of administering an extract or a fraction thereof to a subject suffering from cancer.
본 발명의 추출물 또는 이의 분획물이 최종당화산물을 효과적으로 억제하므로, 암 예방 및 치료에 유용하게 사용될 수 있다.Since the extract of the present invention or a fraction thereof effectively inhibits the final glycated product, it may be usefully used for cancer prevention and treatment.
이하, 본 발명을 실시예, 실험예 및 제조예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Preparation Examples.
단, 하기 실시예, 실험예 및 제조예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예, 실험예 및 제조예에 한정되는 것은 아니다.However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples, and Preparation Examples.
<< 실시예Example 1> 1> 백피가White blood 추출물의 제조 Preparation of Extract
<1-1> <1-1> 백피가White blood 에탄올 추출물 Ethanol extract
증거표본(no. Diab-2008-72)이 한국한의학연구원 한의융합연구본부, 당뇨합병증연구센터 표본실에 보관중인, 백피가(白皮柯)(Lithocarpus dealbatus Hook. f. et Thomas. 또는 Quercus dealbatus Hook. f. et Thomas.)의 줄기를 사용하였다. 경동시장에서 구입한 음건세절한 백피가의 줄기 196 g을 분쇄한 후 1.0 ℓ 에탄올을 넣고, 추출용기에서 상온에서 48시간 동안 3회 반복 추출하여 여과한 후, 구성성분의 분해 및 가수분해를 방지할 수 있도록 농축 시 온도를 40 ~ 45℃ 이하로 유지하며 감압 농축시켜 에탄올 추출물 14.5 g을 수득하였다. A sample of evidence (no. Diab-2008-72) is stored in the Korean Medicine Convergence Research Division, the Korean Diabetes Complication Research Center, Lithocarpus. dealbatus Hook. f. et Thomas. Or Quercus dealbatus Hook. f. et Thomas.) stem. After crushing 196 g of dried dried white skin stems purchased from Kyungdong Market, 1.0 L ethanol was added and extracted by filtering three times for 48 hours at room temperature in an extraction container, and then prevented decomposition and hydrolysis of components. Concentration under reduced pressure while maintaining the temperature at 40 ~ 45 ℃ or less so as to give 14.5 g of ethanol extract.
<1-2> <1-2> 백피가White blood 메탄올 추출물 Methanol extract
상기 실시예 <1-1>의 방법에 따라 백피가 메탄올 추출물 13 g을 제조하였고, 이때 에탄올 대신 메탄올을 사용하였다.According to the method of Example <1-1>, the white skin prepared 13 g of methanol extract, in which methanol was used instead of ethanol.
<1-3> <1-3> 백피가White blood 물 추출물 Water extract
상기 실시예 <1-1>의 방법에 따라 백피가 물 추출물 15.8 g을 제조하였고, 이때 에탄올 대신 물을 사용하였다.According to the method of Example <1-1> to prepare 15.8 g of water extract of Baekpi, water was used instead of ethanol.
<< 실시예Example 2> 2> 백피가White blood 분획물의Fraction 제조 Produce
<2-1><2-1> 백피가White blood 노르말- Normal 헥산Hexane 분획물Fraction
상기 실시예 <1-1>에서 수득한 백피가 에탄올 추출물 12 g에 물 0.5 ℓ와 노르말 헥산 0.5 ℓ를 넣고 혼합한 후 헥산층을 분리하였다. 상기 방법을 3회 반복 수행한 후, 40℃에서 감압 농축시켜 헥산 분획물 3.98 g을 수득하였다.The white skin obtained in Example <1-1> was mixed with 0.5 L of water and 0.5 L of normal hexane in 12 g of ethanol extract, and the hexane layer was separated. The process was repeated three times and then concentrated under reduced pressure at 40 ° C. to yield 3.98 g of hexane fractions.
<2-2> <2-2> 백피가White blood 에틸아세테이트 Ethyl acetate 분획물Fraction
상기 실시예 <2-1>에서 수득한 물층에 에틸아세테이트 0.5 ℓ를 넣어 혼합한 후 에틸아세테이트층을 분리하였다. 상기 방법을 3회 반복 수행한 후, 40℃에서 감압 농축시켜 에틸아세테이트 분획물 56.0 g을 수득하였다.0.5 L of ethyl acetate was added to the water layer obtained in Example <2-1>, and the ethyl acetate layer was separated. The method was repeated three times, and then concentrated under reduced pressure at 40 ° C. to obtain 56.0 g of ethyl acetate fraction.
<2-3><2-3> 백피가White blood 노르말- Normal 부탄올Butanol 분획물Fraction
상기 실시예 <2-2>에서 수득한 물층에 노르말-부탄올 0.5 ℓ를 넣어 혼합한 후 노르말-부탄올층을 분리하였다. 상기 방법을 3회 반복 수행한 후, 40℃에서 감압 농축시켜 노르말-부탄올 분획물 41.4 g을 수득하였다.0.5 L of normal-butanol was added to the water layer obtained in Example <2-2>, and the normal-butanol layer was separated. The process was repeated three times and then concentrated under reduced pressure at 40 ° C. to give 41.4 g of normal-butanol fraction.
<2-4><2-4> 백피가White blood 물 water 분획물Fraction
상기 실시예 <2-3>에서 수득한 물층을 40℃에서 감압 농축시켜 물 분획물 88.6 g을 수득하였다.The water layer obtained in Example <2-3> was concentrated under reduced pressure at 40 ° C. to obtain 88.6 g of a water fraction.
<실험예 1> 최종당화산물 생성억제 효능 분석 Experimental Example 1 Final Glycation Product Inhibition Effect Analysis
상기 <실시예 1>에서 수득한 백피가 추출물 또는 상기 <실시예 2>에서 수득 한 백피가 에탄올 추출물의 분획물의 시험관 내 최종당화산물 생성 억제 효능을 분석하였다. 단백질원으로 소혈청알부민(bovine serum albumin; BSA, 미국 시그마)을 택하였다. BSA를 10 ㎎/㎖의 농도가 되도록 50 mM 인산 완충 용액(phosphate buffer; pH 7.4)에 첨가하여 제조하였다. 당원으로는 0.2 M 과당 및 0.2 M 글루코스가 혼합된 용액을 사용하였다. 상기의 제조된 BSA 용액에 과당 및 글루코스 혼합액을 첨가하였다. 백피가 추출물은 2.5 ㎍/㎖, 5 ㎍/㎖, 10 ㎍/㎖ 또는 25 ㎍/㎖ 농도로 제조하였다. 이때, 디메틸설폭사이드(Dimethylsulfoxide; DMSO)에 녹인 후 15% 트윈(tween) 80을 첨가하였고, 총 DMSO의 함량은 0.2%이었다. 상기 제조된 추출물 또는 이의 분획물을 상기 BSA 및 당의 혼합액에 첨가하여 37℃에서 14일간 배양하였다. 이때, 0.02% 소디움아자이드(sodium azide) 및 안티마이코틱스(antimycotics)를 항박테리아제 및 항진균제로서 첨가하였다. BSA 및 당 혼합액을 배양한 것을 대조군으로서 사용하였고, 추출물을 제조하여, 배양하지 않을 것을 시험군과 대조군의 공시험군(blank)으로서 사용하였다. 한편, 효능의 우수함을 비교할 수 있는 지표인 양성대조군으로서 아미노구아니딘을 사용하였다. 구체적으로는, 아미노구아니딘을 증류수에 용해하여 상기에 기재한 방법으로 37℃에서 18.5 ㎍/㎖, 37 ㎍/㎖ 또는 55.5 ㎍/㎖의 농도로 7일 동안 각각 배양하였다. 모든 배양액은 4개씩 준비하여 최대한 오차를 피하였다. 배양 7일 후 배양액에서 생성된 최종당화산물의 함량을 분석하여 그 결과를 나타내었다. 최종당화산물은 형광, 갈색을 띠고 있으며 교차결합을 할 수 있는 물리화학적인 특성을 지니고 있을 뿐 아니라 세포막 수용체가 인지할 수 있는 배위자를 지니고 있었다. 이러한 특성을 지닌 최종당화산물의 양을 마이크로플레이트 검출기(Microplate reader; Excitation: 350 ㎚, Emission: 450 ㎚)로 측정하여 최종당화산물의 생성 억제 정도를 분석하였다(Vinson, J.A. et al., J. Nutr . Biochem ., 7: 659-663, 1996). 최종당화산물의 생성억제율은 하기의 수학식 1에 따라 계산하였다.The inhibitory effect of the production of the final glycosylated product in vitro of the extract of the white blood extract obtained in Example 1 or the extract of ethanol extract of the white extract obtained in Example 2 was analyzed. Bovine serum albumin (BSA, Sigma, USA) was selected as a protein source. BSA was prepared by adding 50 mM phosphate buffer (pH 7.4) to a concentration of 10 mg / mL. As a sugar source, a solution containing 0.2 M fructose and 0.2 M glucose was used. A fructose and glucose mixture was added to the prepared BSA solution. Baekpiga extract was prepared at a concentration of 2.5 μg / ml, 5 μg / ml, 10 μg / ml or 25 μg / ml. At this time, 15% tween 80 was added after dissolving in dimethylsulfoxide (DMSO), and the total DMSO content was 0.2%. The prepared extract or a fraction thereof was added to the mixture of BSA and sugar and incubated at 37 ° C. for 14 days. At this time, 0.02% sodium azide and antimycotics were added as antibacterial and antifungal agents. Cultures of BSA and sugar mixtures were used as controls, extracts were prepared, and those not cultured were used as blanks of the test and control groups. On the other hand, aminoguanidine was used as a positive control group which can be compared with the excellent efficacy. Specifically, aminoguanidine was dissolved in distilled water and incubated for 7 days at 37 ° C. at a concentration of 18.5 μg / ml, 37 μg / ml or 55.5 μg / ml by the method described above. All cultures were prepared by four to avoid errors as much as possible. After 7 days of culture, the contents of the final glycation product produced in the culture solution were analyzed and the results are shown. The final glycosylated product was fluorescence, brown, and not only possessed physicochemical properties that could cross-link, but also had ligands recognized by cell membrane receptors. The amount of the final glycated product having this property was measured by a microplate reader (Excitation: 350 nm, Emission: 450 nm) to analyze the degree of inhibition of production of the final glycated product (Vinson, JA et al., J. Nutr . Biochem . , 7: 659-663, 1996). The production inhibition rate of the final glycosylated product was calculated according to Equation 1 below.
그 결과, [표 1]에 나타낸 바와 같이, 백피가 에탄올 추출물, 메탄올 추출물 및 물 추출물의 최종당화산물 생성억제효능의 IC50값이 각각 6.56 ㎍/㎖, 12.51 ㎍/㎖ 및 12.98 ㎍/㎖로 나타났다. 이는 양성대조군인 아미노구아니딘(IC50값: 52.96 ㎍/㎖)보다 각각 8.1배, 4.2배 및 4.1배 효능이 현저히 뛰어난 것으로 나타났으며, 특히 추출물 중에서 에탄올 추출물의 효과가 가장 효과적인 것으로 나타났다. 또한, 각각의 분획물도 최종당화산물 억제효능이 우수한 것으로 나타났다. 양성 대조군인 아미노구아니딘보다 에틸아세테이트 분획물은 1.9배, 노르말-부탄올 분획물은 23배, 물 분획물은 1.8배 효능이 우수하였다(표 1). 이에, 백피가 추출물 또는 이의 분획물이 단백질과 당의 결합을 억제하여 최종당화산물의 생성을 강력하게 저해하는 것으로 확인되었고, 최종당화산물 저해 효능이 가장 뛰어난 에탄올 추출물을 하기의 당뇨합병증 효능 분석에 사용하였다. As a result, as shown in [Table 1], the IC 50 values of the final glycation end product inhibitory effect of the ethanol extract, methanol extract and water extract were 6.56 µg / ml, 12.51 µg / ml and 12.98 µg / ml, respectively. appear. It was found to be 8.1 times, 4.2 times and 4.1 times more effective than the positive control aminoguanidine (IC 50 value: 52.96 ㎍ / ml), respectively, and the effect of ethanol extract was particularly effective among the extracts. In addition, each fraction was also found to be excellent in inhibiting the final glycation product. Ethyl acetate fraction was 1.9 times, normal-butanol fraction was 23 times, and water fraction 1.8 times more effective than aminoguanidine, a positive control (Table 1). Accordingly, it was confirmed that Baekpi extract or fractions thereof inhibited the binding of protein and sugar to strongly inhibit the production of the final glycated product, and the ethanol extract having the highest inhibitory effect on the final glycated product was used for the following diabetic complication efficacy analysis. .
(㎍/㎖)density
(Μg / ml)
5
102.5
5
10
46.58±2.00
67.30±3.6724.52 ± 0.87
46.58 ± 2.00
67.30 ± 3.67
6.56±0.43
6.56 ± 0.43
10
255
10
25
45.24±1.05
78.03±0.9324.20 ± 1.03
45.24 ± 1.05
78.03 ± 0.93
12.51±0.49
12.51 ± 0.49
10
255
10
25
45.01±1.54
76.83±1.0223.56 ± 0.91
45.01 ± 1.54
76.83 ± 1.02
12.98±0.85
12.98 ± 0.85
25
5010
25
50
31.63±1.46
48.08±2.8113.90 ± 2.00
31.63 ± 1.46
48.08 ± 2.81
>50
> 50
25
5010
25
50
49.30±1.05
69.51±2.1830.84 ± 3.96
49.30 ± 1.05
69.51 ± 2.18
28.41±1.71
28.41 ± 1.71
1.25
2.50.5
1.25
2.5
28.12±1.41
54.75±0.0015.08 ± 1.68
28.12 ± 1.41
54.75 ± 0.00
2.29±0.02
2.29 ± 0.02
2.5
51.25
2.5
5
48.90±2.20
73.99±3.8622.71 ± 2.48
48.90 ± 2.20
73.99 ± 3.86
30.03±0.20
30.03 ± 0.20
37
55.518.5
37
55.5
33.56±0.51
52.81±2.8115.50 ± 1.79
33.56 ± 0.51
52.81 ± 2.81
52.96±1.95
52.96 ± 1.95
<< 실험예Experimental Example 2> 2> 알도즈Aldoz 환원효소( Reductase ( aldosealdose reductasereductase , , ARAR ) 활성 억제 효능 분석Activity Inhibition Effect Analysis
백피가 추출물 또는 이의 분획물의 시험관 내에서 알도즈 환원효소 활성 억제 효능을 분석하였다. 듀프란(Dufrane; 1984) 방법에 따라 SD 랫트(Sprague-Dawley rat, 250 ~ 280 g)의 안구로부터 천연상태의 알도즈 환원효소를 얻기 위하여, 135 mM Na, K-phosphate buffer(pH 7.0) 및 10 mM 2-mercaptoethanol을, 적출한 수정체와 함께 균질기(Homogenizer)와 초음파분쇄기(Sonicater)를 이용해 분쇄하였다. 14000 rpm에서 30분간 원심분리한 다음 상층액을 0.2 ㎛의 필터에 여과한 후 사용하였다. 상기 과정은 모두 4℃에서 수행하였다. 효소(Enzyme)의 단백질원으로 BSA을 이용하여 라우리(lowry) 방법으로 정량하였다. 135 mM Na, K-phosphate buffer(pH 7.0), 100 mM Lithium sulfate, 0.03 mM NADPH, 0.04 mM DL-glycealdehyde 및 100 ㎍/㎖의 효소 혼합물(mixture)을 0.1% DMSO에 녹인 후 각 농도로 희석한 시료 50 ㎕에 첨가하여 총 부피 1 ㎖가 되도록 한 뒤 37℃에서 10분간 반응시켰다. 이때, 공시험군은 0.04 mM DL-글리세알데하이드(DL-glycealdehyde)를 첨가하지 않은 혼합물을, STD는 135 mM Na, K-phosphate buffer(pH 7.0), 100 mM Lithium sulfate에 50 ㎕ NADP(0.2 ~ 5 μM)를 첨가한 시료를 사용하였다. 시료 0.3 ㎖의 0.5 N HCl을 첨가하여 반응을 종료시킨 뒤, 10 mM 이미다졸(imidazole)이 첨가된 6 M NaOH 1 ㎖을 가하여 60℃에서 10분간 반응시켜 NADP가 형광 산물(fluorescent product)로 전환되는 정도를 측정하였다. 시료는 3회(triplicate) 수행하였다. 효능 정도는 Spectrofluorophotometric detector(Bio-TEK, Synergy HT, USA)를 이용하여 Ex. 360 ㎚, Em. 460 ㎚에서 측정하여, IC50으로 나타내었다. 백피가 추출물은 1 ㎍/㎖, 2.5 ㎍/㎖ 또는 5 ㎍/㎖ 농도로 제조하였다. 비교대조군으로는 우수한 알도즈 환원효소 활성억제제 중의 하나인 3,3-테트라메칠렌글루타르산(3,3-tetramethyleneglutaric acid)을 3.72 ㎍/㎖, 4.66 ㎍/㎖ 또는 5.59 ㎍/㎖의 농도로 제조한 후 알도즈 환원효소 활성 억제효능을 측정하였다.The effect of inhibiting aldose reductase activity in vitro of the extract or fractions thereof was analyzed. 135 mM Na, K-phosphate buffer (pH 7.0) and in order to obtain a natural aldose reductase from the eyes of Sprague-Dawley rats (250 ~ 280 g) according to the Dufrane (1984) method and 10 mM 2-mercaptoethanol was pulverized with the extracted lens using a homogenizer and an ultrasonic grinder (Sonicater). After centrifugation at 14000 rpm for 30 minutes, the supernatant was used after filtering through a 0.2 μm filter. The process was all performed at 4 ℃. Enzyme protein source was quantified by a lowry method using BSA. 135 mM Na, K-phosphate buffer (pH 7.0), 100 mM Lithium sulfate, 0.03 mM NADPH, 0.04 mM DL-glycealdehyde and 100 μg / ml of enzyme mixture were dissolved in 0.1% DMSO and diluted to each concentration. 50 μl of the sample was added to a total volume of 1 ml, followed by reaction at 37 ° C. for 10 minutes. At this time, the test group was a mixture without addition of 0.04 mM DL- glyceraldehyde (DL-glycealdehyde), STD is 50 mM NADP (0.2 ~ 5 in 135 mM Na, K-phosphate buffer (pH 7.0), 100 mM Lithium sulfate Samples with added μM) were used. After completion of the reaction by adding 0.3 ml of 0.5 N HCl sample, 1 ml of 6 M NaOH added with 10 mM imidazole was added and reacted at 60 ° C. for 10 minutes to convert NADP to a fluorescent product. Was measured. Samples were triplicated. Efficacy was measured by using a spectrofluorophotometric detector (Bio-TEK, Synergy HT, USA). 360 nm, Em. Measured at 460 nm, indicated as IC 50 . Baekpiga extract was prepared at a concentration of 1 μg / ml, 2.5 μg / ml or 5 μg / ml. The control group included 3,3-tetramethyleneglutaric acid, one of the excellent aldose reductase inhibitors, at a concentration of 3.72 μg / ml, 4.66 μg / ml or 5.59 μg / ml. After preparation, the inhibitory effect of aldose reductase activity was measured.
그 결과, 하기 [표 2]에서 나타낸 바와 같이, 백피가 에탄올 추출물, 메탄올 추출물 및 물 추출물의 알도즈 환원효소 활성억제 효능은 IC50값이 각각 4.93 ㎍/㎖, 6.23 ㎍/㎖ 및 6.83 ㎍/㎖이었다. 양성대조군인 3,3-테트라메칠렌글루타르산(IC50값: 5.41 ㎍/㎖)과 비교하여 추출물의 효능이 더 우수하였고, 3,3-테트라메칠렌글루타르산은 합성 단일화합물이며 백피가의 추출물 또는 이의 분획물은 한약 추출물인 것을 감안할 때, 백피가 추출물 또는 이의 분획물의 효능이 더 우수한 것으로 나타났다(표 2). As a result, as shown in the following [Table 2], the aldose reductase activity inhibitory effect of the ethanol extract, methanol extract and water extract of Baekpi, IC 50 value of 4.93 ㎍ / ㎖, 6.23 ㎍ / ㎖ and 6.83 ㎍ / Ml. Compared to the positive control 3,3-tetramethylene glutaric acid (IC 50 value: 5.41 μg / ml), the extract was more effective, and 3,3-tetramethylene glutaric acid was a synthetic homogeneous compound Considering that the extract of or the fraction thereof is a Chinese herbal extract, the white skin was shown to have better efficacy of the extract or its fraction (Table 2).
2.5
5One
2.5
5
21.66±1.91
51.59±2.219.55 ± 2.21
21.66 ± 1.91
51.59 ± 2.21
4.93±0.20
4.93 ± 0.20
2.5
5One
2.5
5
18.23±1.43
47.99±1.117.35 ± 1.92
18.23 ± 1.43
47.99 ± 1.11
6.23±0.45
6.23 ± 0.45
2.5
5One
2.5
5
17.96±1.67
47.12±2.127.25 ± 1.72
17.96 ± 1.67
47.12 ± 2.12
6.83±0.32
6.83 ± 0.32
5
102.5
5
10
6.53±1.41
25.71±8.152.45 ± 3.94
6.53 ± 1.41
25.71 ± 8.15
>10
> 10
5
102.5
5
10
40.94±6.55
61.23±2.7429.35 ± 2.17
40.94 ± 6.55
61.23 ± 2.74
7.27±0.74
7.27 ± 0.74
5
102.5
5
10
15.58±8.52
32.90±3.27-3.46 ± 8.65
15.58 ± 8.52
32.90 ± 3.27
>10
> 10
5
102.5
5
10
12.77±5.92
21.28±1.069.93 ± 2.68
12.77 ± 5.92
21.28 ± 1.06
>10
> 10
4.66
5.593.72
4.66
5.59
40.27±1.36
51.58±0.7833.03 ± 4.36
40.27 ± 1.36
51.58 ± 0.78
5.41±0.13
5.41 ± 0.13
<< 실험예Experimental Example 2> 생체 외( 2> in vitro ( exex vivovivo )에서의 At) 항백내장Anti-cataract 효능 분석 Efficacy Analysis
<2-1> <2-1> 백피가White blood 추출물의 준비 Preparation of Extract
상기 실시예 <1-1>에서 수득한 백피가 에탄올 추출물(LD)의 저장액(Stock solution)이 1000배가 되도록 DMSO(Sigma, USA)에 녹인 후, 0.22 ㎛ 필터(syringe filter)(Millipore, USA)로 여과하였다. 양성대조군으로는 에팔레스타트(Epalrestat)를 사용하였다.The white skin obtained in Example <1-1> was dissolved in DMSO (Sigma, USA) so that the stock solution of the ethanol extract (LD) was 1000 times, and then a 0.22 μm filter (Millipore, USA). Filtered). Epalrestat was used as a positive control.
<2-2> 수정체 기관 배양(<2-2> lens organ culture ( organorgan cultureculture ))
생후 4주된 체중 200 g 내외의 흰쥐(Sprague-Dawley)를 사용하였으며, 경추 파열로 동물을 희생시킨 뒤 안구를 적출하여 PBS(Welgen, USA) 1 ㎖가 들어있는 1.5 ㎖ 튜브에 보관하였다. 안구에서 수정체를 분리하기 위해 후방(posterior approach)에서 조심스레 꺼내 홍채와 모양소대를 제거하였고 외과적 손상 (surgical damage)이 없는 온전한 수정체만을 사용하였다(Spector et al., Exp . Eye Research , 1993, 57, 656~667). 배양은 24 웰 플레이트(Nagel Nunc, Denmark)에 수정체를 5 ㎎/ℓ 젠타마이신(Gentamycine)(Gibco, USA)과 0.5 ㎎/ℓ Fungizione(Gibco, USA)이 첨가된 1 ㎖ medium 199(Gibco, USA)에 옮겨 담은 후 5% CO2, 95% 공기(air atmosphere) 및 37℃를 유지하면서 5 ㎍/㎖ 또는 10 ㎍/㎖ 농도의 백피가 추출물을 처리하고 4일 동안 배양하였다(Bradford, M., Analytical Biochemistry , 1976, 72, 248~254). Sugar cataract는 20 mM 자일로스(xylose)(Aldrich, USA)를 첨가하여 유도하였고, 양성대조군은 1 ㎍/㎖ 또는 3 uM epalrestat로 처리하여 배양하였다(Obazawa H.,etal., Invest . Opthalmol , 1974, 13, 204).Sprague-Dawley rats weighing about 200 g at 4 weeks of age were used. The animals were sacrificed by cervical vertebral rupture, and the eyes were extracted and stored in a 1.5 ml tube containing 1 ml of PBS (Welgen, USA). To separate the lens from the eye, it was carefully removed from the posterior approach to remove the iris and plaque and only intact lens without surgical damage was used (Spector et al., Exp . Eye) . Research , 1993, 57, 656-667). The culture was carried out in a 24-well plate (Nagel Nunc, Denmark) in 1 ml medium 199 (Gibco, USA) with 5 mg / l gentamycine (Gibco, USA) and 0.5 mg / l Fungizione (Gibco, USA). ) Was treated with 5% CO 2 , 95% air atmosphere and 37 μg / ml or 10 μg / ml concentrations of Bacillus bark extract and incubated for 4 days (Bradford, M.). , Analytical Biochemistry , 1976, 72, 248-254). Sugar cataract was induced by addition of 20 mM xylose (Aldrich, USA) and positive controls were incubated with 1 μg / ml or 3 uM epalrestat (Obazawa H., et al., Invest . Opthalmol , 1974 , 13, 204).
<2-3> 수정체 혼탁도 측정<2-3> Lens turbidity measurement
상기 실험예 <2-2>에서 배양된 수정체는 4일 동안 CCD 카메라가 연결된 광학 현미경으로 관찰하였다(Chand et al., Exp . Eye Research , 1982, 35, 491~497). 수정체 혼탁도는 Scion image analyzer(Scion Corporation, USA)로 측정하였고 측정수치는 화소(pixel) 당 arbitrary units(AU)으로 표현하였다.The lens cultured in Experimental Example <2-2> was observed under an optical microscope connected to a CCD camera for 4 days (Chand et al., Exp . Eye) . Research , 1982, 35, 491-497). Lens turbidity was measured with a Scion image analyzer (Scion Corporation, USA) and measured values were expressed in arbitrary units per pixel (AU).
그 결과, 도 1에 나타낸 바와 같이, Ex vivo 쥐의 수정체에서의 백피가 추출물의 항백내장 효능은 10 ㎍/㎖ 처리군이 백내장 유도한 날로부터 자일로스(xylose)로 백내장을 유도한 군에 비해 유의성 있게 백내장 유발을 억제하는 것으로 나타났다(*p<0.05, ***p<0.001 vs. 자일로스로 백내장 유발군).As a result, as shown in FIG. 1, Ex The anti-cataract efficacy of cataract extract in rats in vivo was shown to significantly inhibit cataract induction compared to the xylose-induced group from the 10 ㎍ / ml treated group (* p <0.05, *** p <0.001 vs. xylose-induced cataract group).
<< 제조예Manufacturing example 1> 약학적 제제의 제조 1> Preparation of Pharmaceutical Formulations
<1-1> <1-1> 산제의Powder 제조 Produce
본 발명의 실시예 <1-1>의 에탄올 추출물 2 g2 g of ethanol extract of Example <1-1> of the present invention
유당 1 g1 g lactose
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above components were mixed and packed in airtight bags to prepare powders.
<1-2> 정제의 제조<1-2> Preparation of Tablet
본 발명의 실시예 <1-1>의 에탄올 추출물 100 ㎎100 mg of ethanol extract of Example <1-1> of the present invention
옥수수전분 100 ㎎
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<1-3> 캡슐제의 제조<1-3> Preparation of Capsule
본 발명의 실시예 <1-3>의 물 추출물 100 ㎎100 mg of water extract of Example <1-3> of the present invention
옥수수전분 100 ㎎
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
<1-4> 환의 제조<1-4> Preparation of the ring
본 발명의 실시예 <1-3>의 물 추출물 1 g1 g of the water extract of Example <1-3> of the present invention
유당 1.5 gLactose 1.5 g
글리세린 1 g1 g of glycerin
자일리톨 0.5 gXylitol 0.5 g
상기의 성분을 혼합한 후, 통상의 방법에 따라 1 환 당 4 g이 되도록 제조하였다.After mixing the above components, it was prepared to be 4 g per ring in a conventional manner.
<1-5> 과립의 제조<1-5> Preparation of Granules
본발명의 실시예 <2-1>의 노르말-헥산 분획물 150 ㎎150 mg of the normal-hexane fraction of Example <2-1> of the present invention
대두 추출물 50 ㎎Soybean Extract 50mg
포도당 200 ㎎Glucose 200 mg
전분 600 ㎎600 mg of starch
상기의 성분을 혼합한 후, 30% 에탄올 100 ㎎을 첨가하여 섭씨 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다.After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, which were then filled into fabrics.
<< 제조예Manufacturing example 2> 식품의 제조 2> Manufacture of food
본 발명의 백피가 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the extract of Baekpi of the present invention were prepared as follows.
<2-1> 밀가루 식품의 제조<2-1> Production of flour food
본 발명의 실시예 <2-2>의 에틸아세테이트 분획물 0.5~5.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하였다.0.5-5.0 parts by weight of the ethyl acetate fraction of Example <2-2> of the present invention was added to flour, and bread, cake, cookies, crackers, and noodles were prepared using this mixture.
<2-2> <2-2> 스프soup 및 육즙( And juicy ( graviesgravies )의 제조Manufacturing
본 발명의 실시예 <2-2>의 에틸아세테이트 분획물 0.1~5.0 중량부를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1 to 5.0 parts by weight of the ethyl acetate fraction of Example <2-2> of the present invention was added to soups and broths to prepare meat products for health promotion, soups and noodles for noodles.
<2-3> 그라운드 <2-3> ground 비프(ground beef)의Beef 제조 Produce
본 발명의 실시예 <2-4>의 물 분획물 10 중량부를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.10 parts by weight of the water fraction of Example <2-4> of the present invention was added to the ground beef to prepare a ground beef for health promotion.
<2-4> 유제품(<2-4> dairy products ( dairydairy productsproducts )의 제조Manufacturing
본 발명의 실시예 <2-4>의 물 분획물 5~10 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5-10 parts by weight of the water fraction of Example <2-4> of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
<2-5> <2-5> 선식의Solar 제조 Produce
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
본 발명의 실시예 <2-3>의 노르말-부탄올 분획물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The normal-butanol fraction of Example <2-3> of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a spray and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 실시예 <2-3>의 노르말-부탄올 분획물을 다음의 비율로 배합하여 제조하였다.The grains, seeds and the normal-butanol fractions of Example <2-3> prepared above were prepared by combining the following ratios.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
본 발명의 실시예 <2-3>의 노르말-부탄올 분획물(3 중량부),Normal-butanol fraction (3 parts by weight) of Example <2-3> of the present invention,
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 중량부)Foxglove (0.5 part by weight)
<< 제조예Manufacturing example 3> 음료의 제조 3> Manufacturing of beverage
<3-1> <3-1> 건강음료의Health drink 제조 Produce
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 본 발명의 실시예 <1-1>의 에탄올 추출물 5 g을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 제조하였다.Substances such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%), and 5 g of ethanol extract of Example <1-1> of the present invention It was prepared by homogeneously blending and sterilizing instantaneously and then packing it in a small packaging container such as a glass bottle or a plastic bottle.
<3-2> 야채 주스의 제조<3-2> Preparation of Vegetable Juice
본 발명의 실시예 <1-3>의 물 추출물 5 g을 토마토 또는 당근 주스 1,000 ㎖에 가하여 야채 주스를 제조하였다.5 g of the water extract of Example <1-3> of the present invention was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice.
<3-3> 과일 주스의 제조<3-3> Preparation of Fruit Juice
본 발명의 실시예 <1-3>의 물 추출물 1 g을 사과 또는 포도 주스 1,000 ㎖ 에 가하여 과일 주스를 제조하였다.1 g of the water extract of Example <1-3> of the present invention was added to 1,000 ml of apple or grape juice to prepare a fruit juice.
<< 제조예Manufacturing example 4> 사료첨가제의 제조 4> Preparation of feed additive
본 발명자들을 실시예 <1-3>의 물 추출물을 유효성분으로 하여 하기와 같은 조성으로 사료첨가제를 제조하였다.Using the water extract of Example <1-3> as an active ingredient, the present inventors prepared a feed additive with the following composition.
<사료첨가제의 조성><The composition of the feed additive>
본 발명의 실시예 <1-3>의 물 추출물: 0.1 ~ 20% 중량부,Water extract of Example <1-3> of the present invention: 0.1 to 20% by weight,
지방분해효소(Lipase): 0.001 ~ 0.01% 중량부, Lipase: 0.001 to 0.01% by weight,
제 3 인산칼슘: 1 ~ 20% 중량부, Tertiary calcium phosphate: 1-20% by weight,
비타민 E: 0.01 ~ 0.1% 중량부, Vitamin E: 0.01-0.1% by weight,
효소 분말: 1 ~ 10% 중량부, Enzyme powder: 1 to 10% by weight,
유산균: 0.1 ~ 10% 중량부, Lactic acid bacteria: 0.1 to 10% by weight,
바실러스(Bacillus) 배양액: 0.01 ~ 10% 중량부, 및Bacillus culture medium: 0.01 to 10% by weight, and
포도당: 20 ~ 90% 중량부.Glucose: 20 to 90% by weight.
본 발명의 백피가 추출물 또는 이의 분획물은 당뇨합병증의 예방 및 지연에 효과적이며, 노화방지에 효과적인 천연 추출물로서, 당뇨합병증, 노화방지 및 지연용, 암 예방 및 치료용 조성물로 약학적으로 이용가능할 뿐 아니라 건강기능식품 또는 기능성 사료첨가제로서도 유용하게 이용될 수 있다.Baekpiga extract or fractions thereof of the present invention is effective in preventing and delaying diabetic complications, and is a natural extract effective in preventing aging, and is only pharmaceutically usable as a composition for diabetic complications, anti-aging and delaying, cancer prevention and treatment. In addition, it can be usefully used as a dietary supplement or a functional feed additive.
도 1은 생체 외(ex vivo) 실험을 통한 백피가 에탄올 추출물의 수정체 혼탁 지연 효과를 사진촬영결과(상) 및 분석결과(하)로 나타낸 그림이다.1 is ex vivo ( ex In vivo experiment shows that the chloroplast delayed lens turbidity of the ethanol extract is shown in the photographs (top) and analysis (bottom).
Claims (14)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090114838A KR101461532B1 (en) | 2009-11-25 | 2009-11-25 | The composition for the prevention and treatment of diabetic complications containing the extracts or fractions of herbal medicine as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090114838A KR101461532B1 (en) | 2009-11-25 | 2009-11-25 | The composition for the prevention and treatment of diabetic complications containing the extracts or fractions of herbal medicine as active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110058157A true KR20110058157A (en) | 2011-06-01 |
| KR101461532B1 KR101461532B1 (en) | 2014-11-14 |
Family
ID=44393681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090114838A KR101461532B1 (en) | 2009-11-25 | 2009-11-25 | The composition for the prevention and treatment of diabetic complications containing the extracts or fractions of herbal medicine as active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101461532B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101841023B1 (en) | 2017-04-06 | 2018-03-22 | 한국식품연구원 | Novel Bacillus subtilis strain having advanced glycation end product inhibitory activity effects and use of the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124102A2 (en) * | 2006-04-21 | 2007-11-01 | Western Holdings, Llc | Preparation and use of phlorizin compositions |
-
2009
- 2009-11-25 KR KR1020090114838A patent/KR101461532B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR101461532B1 (en) | 2014-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101243243B1 (en) | Composition for the prevention and treatment of diabetic complications containing the extracts or fractions of Litsea japonica as active ingredient | |
| KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
| KR101261029B1 (en) | Composition for preventing or improving the diabete containing suaeda japonica | |
| KR100926454B1 (en) | The composition comprising the extracts, fractions and the isolated compounds of Rhus verniciflua for prevention and treatment of diabetic complications | |
| KR101226824B1 (en) | A composition comprising the extract of Sorghum bicolor L. Moench as an active ingredient for preventing and treating inflammatory disease | |
| KR20110058157A (en) | The composition for the prevention and treatment of diabetic complications containing the extracts or fractions of herbal medicine as active ingredient | |
| KR101681980B1 (en) | Compositions for prevention or treatment of diabetic complications comprising extract of Colona auricaulata | |
| EP2684566B1 (en) | Pharmaceutical composition for preventing and treating complications of diabetes containing a homonoia riparia extract or a fraction thereof as an active ingredient | |
| KR101115505B1 (en) | The composition for the prevention and treatment of diabetic complications containing the extracts or fractions of herbal medicine as active ingredient | |
| KR101449670B1 (en) | Composition for preventing or treating diabetes or complications of diabetes mellitus comprising Rhododendron mucronulatum for. albiflorum extract | |
| KR101605305B1 (en) | Composition comprising broussonetia kazinoki extract for preventing and treating diabetic complication | |
| KR101273644B1 (en) | Composition for the prevention and treatment of diabetic complications containing the extracts or fractions of Spenceria ramalana as active ingredient | |
| KR100973941B1 (en) | Compositions and functional food for prevention and treatment of diabetic complications using Osteomeles schwerine | |
| KR101366611B1 (en) | Composition for the prevention and treatment of diabetic complications containing the extracts or fractions of Brandisia hancei Hook. f. as active ingredient | |
| KR20100042139A (en) | The composition comprising enzyme-treated extracts of momordica charantia l. for the prevention and treatment of diabetic complications | |
| KR100671793B1 (en) | Pharmaceutical compositions and functional food comprising Extract of Rumex japonicus, Extract of Rumex Crispus | |
| KR101325215B1 (en) | Pharmaceutical composition for the prevention and treatment of diabetic complications containing the extracts or fractions of Melastoma sanguineum as active ingredient | |
| KR101276293B1 (en) | Composition comprising extract from geranium thunbergii for preventing or treating various diabetic complications | |
| KR101219185B1 (en) | Novel biphenyl compound or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for preventing or treating complications of diabetes mellitus | |
| KR101272314B1 (en) | Composition for prevention and treatment of diabetic complications comprising Quercitrine gallate as an active ingredient | |
| KR100887234B1 (en) | Composition for preventing or improving diabetes induced complication containing phellinus baumii extract | |
| KR101227036B1 (en) | Antidiabetic composition with the extract of tronadora | |
| KR101437647B1 (en) | Compositions and functional food for prevention or treatment of diabetic complications comprising using extract of Carpinus cordata | |
| WO2012021038A2 (en) | Composition for preventing and treating diabetes complications including spenceria ramalana extract or fraction thereof as active ingredient | |
| KR20050089238A (en) | Composition comprising alcohol extract of coptis rhizoma or berberine isolated from them for prevention and treatment of diabetic complications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20171102 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190926 Year of fee payment: 6 |